Anouk M.D. Becker
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Anouk M.D. Becker has a total of 20 co-authors. Here are the top co-authors by number of shared publications:
- Albert J. R. Heck
Utrecht University Padualaan 8
1 shared publication - Alper Cevirgel
Radboudumc, Nijmegen
1 shared publication - Arthur E. H. Bentlage
Sanquin Research and Landsteiner Laboratory, Amsterdam University Medical Center, University of Amsterdam, Amsterdam (The Netherlands)
1 shared publication - Camille M. Le Gall
Radboudumc, Nijmegen
1 shared publication - Carl Gustav Figdor
Department of Medical BioSciences, Radboud University Medical Center, Nijmegen, the Netherlands
1 shared publication - Duco van Dalen
Radboudumc, Nijmegen
1 shared publication
Latest Publications
- Open Access
- 15 February 2019
- Published by Cold Spring Harbor Laboratory in bioRxiv
- p. 551382
Functional diversification of hybridoma produced antibodies by CRISPR/HDR genomic engineering
Hybridoma technology is instrumental for the development of novel antibody therapeutics and diagnostics. Recent preclinical and clinical studies highlight the importance of antibody isotype for therapeutic efficacy. However, since the sequence encoding the constant domains is fixed, tuning antibody function in hybridomas has been restricted. Here, we demonstrate a versatile CRISPR/HDR platform to rapidly engineer the constant immunoglobulin domains to obtain recombinant hybridomas which secrete antibodies in the preferred format, species and isotype. Using this platform, we obtained recombinant hybridomas secreting Fab’ fragments, isotype switched chimeric antibodies, and Fc-silent mutants. These antibody products are stable, retain their antigen specificity, and display their intrinsic Fc-effector functions in vitro and in vivo. Furthermore, we can site-specifically attach cargo to these antibody products via chemo-enzymatic modification. We believe this versatile platform facilitates antibody engineering for the entire scientific community, empowering preclinical antibody research.One Sentence Summary: We demonstrate a universal CRISPR/HDR based platform for rapid genetic engineering of hybridomas to obtain functionally diverse antibody isotype panels in the species and format of choice.
- 15 February 2019
- Published by Cold Spring Harbor Laboratory in bioRxiv
- p. 551382
Open AccessFunctional diversification of hybridoma produced antibodies by CRISPR/HDR genomic engineering
Hybridoma technology is instrumental for the development of novel antibody therapeutics and diagnostics. Recent preclinical and clinical studies highlight the importance of antibody isotype for therapeutic efficacy. However, since the sequence encoding the constant domains is fixed, tuning antibody function in hybridomas has been restricted. Here, we demonstrate a versatile CRISPR/HDR platform to rapidly engineer the constant immunoglobulin domains to obtain recombinant hybridomas which secrete antibodies in the preferred format, species and isotype. Using this platform, we obtained recombinant hybridomas secreting Fab’ fragments, isotype switched chimeric antibodies, and Fc-silent mutants. These antibody products are stable, retain their antigen specificity, and display their intrinsic Fc-effector functions in vitro and in vivo. Furthermore, we can site-specifically attach cargo to these antibody products via chemo-enzymatic modification. We believe this versatile platform facilitates antibody engineering for the entire scientific community, empowering preclinical antibody research.One Sentence Summary: We demonstrate a universal CRISPR/HDR based platform for rapid genetic engineering of hybridomas to obtain functionally diverse antibody isotype panels in the species and format of choice.